Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6381MR)

This product GTTS-WQ6381MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000133.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6381MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1872MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ13704MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ8884MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ1997MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ5794MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ5553MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ15116MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ468MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW